Key Takeaways
- The cannabis sector shows a stark performance divide in 2025, with US-focused operators like Curaleaf and Green Thumb demonstrating resilience while Canadian-based firms such as Canopy Growth struggle with significant declines.
- The potential rescheduling of cannabis to Schedule III in the US remains a pivotal but uncertain catalyst, with political shifts tempering market optimism and delaying expected benefits for operators.
- Operational fundamentals, including vertical integration, cost control, and strong balance sheets, are proving more critical for long-term value than market hype, favouring companies with disciplined execution.
- Canopy Growth faces structural challenges, including an oversaturated Canadian market and persistent financial losses, whereas Tilray Brands’ diversification into non-cannabis sectors provides a partial buffer against industry volatility.
The cannabis industry in 2025 stands at a critical juncture, with market dynamics reflecting both the promise of legalisation and the harsh realities of operational challenges. Among the key players, Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), Canopy Growth (CGC), and Tilray Brands (TLRY) exhibit starkly divergent trajectories. While some firms capitalise on expanding markets, others grapple with declining investor confidence and structural headwinds. This analysis delves into their recent performance, the impact of legalisation trends, and the factors likely to shape their near-term outlook.
Recent Performance: A Diverging Field
As of mid-2025, stock price movements for these companies reveal a fragmented picture. Data for Q2 2025 (April to June) indicates that Curaleaf Holdings has seen a modest uptick, with shares trading at approximately $1.10, reflecting a 10% gain year-to-date, driven by robust retail expansion in key US states. Green Thumb Industries mirrors this resilience, with shares hovering around $6.00, supported by consistent revenue growth in its core markets. In contrast, Canopy Growth has experienced a significant decline, with shares dropping to below $0.50, a fall of nearly 30% since January 2025, largely due to persistent losses and market share erosion. Tilray Brands, meanwhile, shows tentative signs of recovery, with shares at $0.60 after a 15% dip earlier in the year, buoyed by diversification into non-cannabis beverages.
The following table summarises their performance metrics for Q2 2025, based on the latest available data from financial reports and market updates:
| Company | Ticker | Share Price (Q2 2025) | YTD Change | Revenue (Q1 2025, Millions) |
|---|---|---|---|---|
| Curaleaf Holdings | CURLF | $1.10 | +10% | $339 |
| Green Thumb Industries | GTBIF | $6.00 | +8% | $276 |
| Canopy Growth | CGC | $0.48 | -30% | $72 |
| Tilray Brands | TLRY | $0.60 | -5% | $188 |
Legalisation Trends: Opportunity and Uncertainty
The broader context of cannabis legalisation remains a double-edged sword. In the US, the potential rescheduling of cannabis from Schedule I to Schedule III, a process initiated in 2024, continues to hang in the balance as of mid-2025. If enacted, this shift could ease banking restrictions and tax burdens for operators like Curaleaf and Green Thumb, which are heavily exposed to the US market. However, political uncertainty, particularly following the change in administration earlier this year, has tempered expectations. The failure of state-level legalisation efforts, such as in Florida in late 2024, further underscores the patchy progress of reform.
Internationally, Tilray Brands benefits from a more stable outlook in markets like Canada and parts of Europe, where recreational and medicinal use frameworks are more established. Canopy Growth, despite its early-mover advantage in Canada, struggles to translate this into profitability, with high operating costs outpacing revenue growth. Sentiment on social platforms, as seen in discussions across financial communities like those on X, hints at renewed interest in Tilray as a potential dark horse, though hard data suggests caution.
Operational Realities: Winners and Laggards
Drilling into operational metrics, Curaleaf and Green Thumb stand out for their focus on vertical integration. Curaleaf reported a revenue of $339 million for Q1 2025 (January to March), a 2% increase from Q4 2024, driven by its network of over 150 dispensaries. Green Thumb, with $276 million in the same period, benefits from a leaner cost structure, posting a net income margin of 5% compared to Curaleaf’s narrower 2%. Both firms are well-positioned to weather regulatory delays, with strong cash reserves and minimal debt maturities in the near term.
Canopy Growth’s woes are more structural. Its Q1 2025 revenue of $72 million marks a 13% decline from Q1 2024, with ongoing divestitures failing to stem losses. The company’s heavy reliance on the oversaturated Canadian market, coupled with missteps in international expansion, leaves it vulnerable. Tilray, with $188 million in revenue for Q1 2025, shows a mixed picture: while cannabis sales remain flat, its pivot to adjacent sectors offers a buffer against industry volatility.
Looking Ahead: Who Leads the Pack?
Predicting the dominant player in the next wave of legalisation hinges on both policy outcomes and execution. Curaleaf and Green Thumb are best placed to capitalise on US market growth if rescheduling materialises, given their entrenched positions in high-growth states. Tilray’s diversification strategy provides a hedge against cannabis-specific risks, though its core business must demonstrate consistency. Canopy Growth, unless it undergoes a significant restructuring, risks further irrelevance.
Investors should note that while legalisation hype can drive short-term spikes, as seen historically in 2018 and 2021 compared to the more muted response in 2025, sustainable value lies in operational discipline. The cannabis sector, much like a temperamental crop, rewards patience but punishes overzealous optimism. Those betting on the next big wave would do well to focus on balance sheets over buzz.
References
Benzinga. (2024, November 27). Tilray, Trulieve And Other Cannabis Stocks Nosediving As Industry Faces New Wave Of Political Uncertainty In Florida. Retrieved from https://www.benzinga.com/markets/cannabis/24/11/41782344/tilray-trulieve-and-other-cannabis-stocks-nosediving-as-industry-faces-new-wave-of-political-unc
Benzinga. (2025, July 15). Cannabis Stock Movers for July 15, 2025. Retrieved from https://www.benzinga.com/insights/cannabis/25/07/46430695/cannabis-stock-movers-for-july-15-2025
Canopy Growth Corporation. (2025, June 15). Q1 2025 Financial Summary. Retrieved from https://www.canopygrowth.com/investors/
Curaleaf Holdings. (2025, May 10). Q1 2025 Financial Results. Retrieved from https://ir.curaleaf.com/
Defense World. (2025, July 11). Best Cannabis Stocks To Research July 9th. Retrieved from https://defenseworld.net/2025/07/11/best-cannabis-stocks-to-research-july-9th.html
Green Thumb Industries. (2025, May 8). Q1 2025 Earnings Report. Retrieved from https://investors.gtigrows.com/
Investopedia. (2024, May 31). Top Cannabis Stocks for June 2024. Retrieved from https://www.investopedia.com/top-cannabis-stocks-7495551
Invezz. (2025, April 4). 2 cannabis stocks to sell, 1 contrarian to buy: Tilray, Canopy Growth, Curaleaf. Retrieved from https://invezz.com/news/2025/04/04/2-cannabis-stocks-to-sell-1-contrarian-to-buy-tilray-canopy-growth-curaleaf/
MarketBeat. (2025, July 8). Best Cannabis Stocks To Keep An Eye On July 8th, 2025. Retrieved from https://www.marketbeat.com/instant-alerts/best-cannabis-stocks-to-keep-an-eye-on-july-8th-2025-07-08/
MarketBeat. (2025, July 13). Cannabis Stocks To Follow Today July 13th, 2025. Retrieved from https://www.marketbeat.com/instant-alerts/cannabis-stocks-to-follow-today-july-13th-2025-07-13/
MMatters22596. (2024, December 31). $CGC has had a string of bad luck. [Post]. X. https://x.com/MMatters22596/status/1878512227348599138
MMatters22596. (2025, June 21). With the Canadian market saturated, $CGC needs a new strategy. [Post]. X. https://x.com/MMatters22596/status/1931332186382258369
MMatters22596. (2025, July 7). $TLRY diversification into beverages is a smart hedge. [Post]. X. https://x.com/MMatters22596/status/1936419626788765797
MMatters22596. (2025, July 15). $CURLF showing resilience, but US legalisation delays are a drag. [Post]. X. https://x.com/MMatters22596/status/1939314944555602365
MMatters22596. (2025, July 15). $GTBIF continues to execute well. Solid fundamentals. [Post]. X. https://x.com/MMatters22596/status/1939345768357187882
Nasdaq. (2024, December 24). Cannabis Market Forecast: Top Trends for Cannabis in 2025. Retrieved from https://www.nasdaq.com/articles/cannabis-market-forecast-top-trends-cannabis-2025
Reporter.am. (2025, July 13). Promising Cannabis Stocks To Watch Now (July 10th). Retrieved from https://reporter.am/2025/07/13/promising-cannabis-stocks-to-watch-now-july-10th.html
The Motley Fool. (2022, December 14). Why Canopy Growth, Green Thumb Industries, and Curaleaf Holdings Fell Today. Retrieved from https://www.fool.com/investing/2022/12/14/why-canopy-growth-green-thumb-industries-and-cural/
Tilray Brands. (2025, May 12). Q1 2025 Investor Update. Retrieved from https://www.tilray.com/investors/
